91国内精品久久久久精品一本91福利共享久久精品|糖心vlog在线人妻高清字幕91啦|人妻在线中文字幕中文字幕人妻久久久久|成人麻豆视频|不卡av中文字幕|国产高清精品一区|国产精品久久久久久吹潮天美传媒|中文字幕一区精品|91丨色丨国产熟女|91九色丨porny丨,天美传媒97a∨久久久久久精品国产尤物,91久久精品久久国产性色也91电影一区二区三区中文精品字幕 ,国产在线91九色

更安全更長(zhǎng)效的iNSC-DAP帕金森細(xì)胞療法

帕金森病（Parkinson’s disease，PD）是最常見(jiàn)的神經(jīng)系統(tǒng)退行性疾病之一

流行病學(xué)顯示患病率為15-328/10萬(wàn)人口,，平均發(fā)病年齡60歲

65歲以上人群的發(fā)病率為1.7%,。PD病人確診后的平均預(yù)期壽命是7-14年

2005年中國(guó)大約有200萬(wàn)PD患者，預(yù)計(jì)到2030年中國(guó)的PD患者將接近500萬(wàn),，而全球的PD患者將超過(guò)870萬(wàn)

PD的病因及發(fā)病機(jī)制尚未明確，可能與遺傳因素、環(huán)境因素及社會(huì)因素等相關(guān)

PD的主要病理改變?yōu)橹心X黑質(zhì)致密部多巴胺（dopamine,，DA）能神經(jīng)元發(fā)生退行性病變和丟失，藍(lán)斑神經(jīng)元色素脫失,，黑質(zhì)色素變淡及出現(xiàn)路易小體

PD的神經(jīng)生化改變?yōu)橹心X黑質(zhì)致密部DA神經(jīng)元脫失導(dǎo)致紋狀體內(nèi)DA含量顯著性減少

而黑質(zhì)紋狀體系統(tǒng)中與DA功能拮抗的乙酰膽堿作用相對(duì)亢進(jìn),，DA與乙酰膽堿平衡失調(diào)從而造成運(yùn)動(dòng)功能障礙

主要臨床表現(xiàn)有運(yùn)動(dòng)癥狀和非運(yùn)動(dòng)癥狀，運(yùn)動(dòng)癥狀主要表現(xiàn)為靜止性震顫,，肌強(qiáng)直或肌張力增高,，運(yùn)動(dòng)遲緩及姿勢(shì)步態(tài)異常

非運(yùn)動(dòng)癥狀主要包括認(rèn)知/精神異常（抑郁或焦慮等精神障礙），睡眠障礙,，自主神經(jīng)功能障礙及感覺(jué)障礙

PD給患者自身帶來(lái)極大痛苦,，給家庭和社會(huì)造成沉重負(fù)擔(dān)

但臨床上尚無(wú)治愈PD的有效治療方案，目前的治療方法主要是對(duì)癥治療,，從減輕病痛,、延緩疾病發(fā)展和提高患者的生活質(zhì)量著手

干細(xì)胞療法由于能補(bǔ)充、替代缺失的多巴胺能神經(jīng)元,，恢復(fù)神經(jīng)元信號(hào)傳導(dǎo),，而有望成為治療帕金森病有效途徑

Safer and more long-term effective iNSC DAP Parkinson's cell therapy

Parkinson's disease (PD) is one of the most common neurodegenerative diseases. Epidemiology shows that the prevalence rate is 15-328/100000 people, the average age of onset is 60 years old, and the incidence rate of people over 65 years old is 1.7%. The average life expectancy of PD patients after diagnosis is 7-14 years. In 2005, there were approximately 2 million PD patients in China, and it is expected that by 2030, the number of PD patients in China will approach 5 million, while the global number of PD patients will exceed 8.7 million. The etiology and pathogenesis of PD are not yet clear, and may be related to genetic, environmental, and social factors.

The main pathological changes of PD are degenerative changes and loss of dopamine (DA) neurons in the substantia nigra pars compacta of the midbrain, loss of pigmentation in locus coeruleus neurons, fading of melanin and appearance of Lewy bodies. The neurobiochemical changes of PD are the loss of DA neurons in the substantia nigra pars compacta of the midbrain, leading to a significant decrease in DA content in the striatum, while acetylcholine, which antagonizes DA function, is relatively overactive in the nigrostriatal system. The balance between DA and acetylcholine is disrupted, resulting in motor dysfunction.

The main clinical manifestations include motor symptoms and non motor symptoms. Motor symptoms mainly include static tremors, muscle rigidity or increased muscle tone, bradykinesia, and abnormal posture and gait. Non motor symptoms mainly include cognitive/psychiatric disorders (such as depression or anxiety), sleep disorders, autonomic dysfunction, and sensory disorders. PD brings great pain to patients themselves and imposes a heavy burden on families and society.

However, there is currently no effective treatment plan for PD in clinical practice. The main treatment method is symptomatic treatment, starting from reducing pain, delaying disease development, and improving patients' quality of life. Stem cell therapy is expected to become an effective way to treat Parkinson's disease due to its ability to supplement and replace missing dopaminergic neurons, restore neuronal signal transduction.

神經(jīng)干細(xì)胞是一類(lèi)來(lái)源于神經(jīng)系統(tǒng)的干細(xì)胞,，具有自我更新能力

可通過(guò)不對(duì)稱(chēng)細(xì)胞增殖,、分化，產(chǎn)生子代以及分化為神經(jīng)元,、星形膠質(zhì)細(xì)胞,、少突膠質(zhì)細(xì)胞等神經(jīng)細(xì)胞

利用細(xì)胞重編程技術(shù)平臺(tái)和神經(jīng)細(xì)胞分化平臺(tái)，從成體血液細(xì)胞獲得了神經(jīng)干細(xì)胞（iNSCs）作為種子細(xì)胞,，實(shí)現(xiàn)自體移植,，可針對(duì)性的治療帕金森等多種神經(jīng)系統(tǒng)疾病和損傷

這樣，還可以一并解決神經(jīng)干細(xì)胞來(lái)源不足及倫理問(wèn)題

iNSCs技術(shù)具有完全的自主知識(shí)產(chǎn)權(quán),，擁有中國(guó)美國(guó)多項(xiàng)發(fā)明專(zhuān)利

從神經(jīng)干細(xì)胞的發(fā)現(xiàn)到分離移植治療疾病,，為多種神經(jīng)系統(tǒng)疾病特別是神經(jīng)系統(tǒng)退行性疾病的治療帶來(lái)新的希望

Neural stem cells are a type of stem cell derived from the nervous system, with self-renewal ability. It can generate offspring and differentiate into neurons, astrocytes, oligodendrocytes and other nerve cells through asymmetric cell proliferation and differentiation.

Using cell reprogramming technology platform and neural cell differentiation platform, neural stem cells (iNSCs) were obtained from adult blood cells as seed cells for autologous transplantation, which can be used for targeted treatment of various neurological diseases and injuries such as Parkinson's. In this way, we can also address the issue of insufficient sources of neural stem cells and ethical concerns.

INSCs technology has complete independent intellectual property rights and holds multiple invention patents in China and the United States. The discovery of neural stem cells and their isolation and transplantation for disease treatment have brought new hope for the treatment of various neurological diseases, especially neurodegenerative diseases.